Recce Pharmaceuticals has reached the midpoint in its Phase II clinical trial for topical gel R327G, aimed at treating skin infections.

Walgreens is leveraging its pharmacy network to enhance patient recruitment and real-world evidence services for biopharma, emphasizing improved access and representation in clinical trials.

Zymeworks' Ziihera (zanidatamab) receives accelerated approval from the FDA for treating HER2-positive biliary tract cancer (BTC).

Regen BioPharma is advancing HemaXellerate™, a stem cell-derived therapy, into a Phase 1 clinical trial following FDA clearance, initially targeting aplastic anemia.

Gravitas Medical's Entarik system has received its second FDA clearance, making it the only smart enteral nutrition delivery system for neonates.

BioAdaptives Inc. has secured Institutional Review Board (IRB) approval to commence a human clinical trial for its weight management product, Zeranovia™.

Protara Therapeutics' TARA-002 demonstrated a 72% six-month complete response rate in NMIBC patients across various BCG exposure statuses.

The FDA has removed the clinical hold on Ocugen's investigational new drug application for OCU200, a novel treatment for diabetic macular edema (DME).

INmune Bio completed enrollment for its Phase 2 Alzheimer’s Disease trial (AD02) focused on early AD patients with elevated neuroinflammation biomarkers.

Nanoscope Therapeutics has licensed the CatCh technology from Max Planck Innovation to boost the light sensitivity of its MCO-010 gene therapy.

UNITY Biotechnology's UBX1325 (foselutoclax) is under development as a novel senolytic therapeutic for diabetic macular edema (DME).

Biofrontera has locked the database for its Phase 3 trial evaluating Ameluz®-PDT for superficial basal cell carcinoma (sBCC) treatment.

Pilatus Biosciences' PLT012 has been granted Orphan Drug Designation by the FDA for the treatment of liver and intrahepatic bile duct cancers (HCC/ICCA).

Acelyrin reported a strong cash position of $788.4 million, expected to fund operations through key clinical milestones in its autoimmune and inflammatory disease programs.

ME Therapeutics is progressing its anti-G-CSF antibody candidate, h1B11-12, towards first-in-human clinical trials, with GMP production anticipated in the second half of 2025.

Immunic's phase 3 ENSURE program for vidofludimus calcium in relapsing multiple sclerosis (RMS) continues as planned after a positive interim futility analysis.

A class action lawsuit has been filed against Cassava Sciences, alleging securities fraud related to its Alzheimer's drug candidate, simufilam.

CorMedix reported preliminary unaudited net revenue of approximately $31 million for Q4 2024 and $43 million for FY 2024, exceeding previous guidance.

Immunic's Phase 3 ENSURE program for relapsing multiple sclerosis (RMS) continues as planned after a positive interim analysis by the Independent Data Monitoring Committee.

MAIA Biotechnology's THIO-101, sequenced with cemiplimab, demonstrates encouraging efficacy in advanced non-small cell lung cancer (NSCLC) patients who have failed multiple prior therapies.